OncoMatch/Clinical Trials/NCT06911333
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Is NCT06911333 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AD1208 for solid tumor, adult.
Treatment: AD1208 — The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are: * Which dosage of AD1208 is safe and tolerable for participants? * What medical problems do participants have when taking AD1208? Participants will: * Take drug AD1208 every day up to 1 cycle at the least. * Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards. * Keep a diary of any adverse events and administrated drug
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
solid tumors that have relapsed or are refractory following the last line of treatment and for which prior standard therapy has been ineffective, standard therapy does not exist or is not considered appropriate
Cannot have received: anticancer monoclonal antibody
prior anticancer monoclonal antibody treatment or investigational therapy
Cannot have received: chemotherapy
prior any chemotherapy
Cannot have received: radiation therapy
prior radiotherapy
Cannot have received: major surgery
Major surgery
Lab requirements
Blood counts
adequate hematologic function confirmed based on the screening laboratory test within 2 weeks prior to the first administration of IP
Kidney function
adequate renal function confirmed based on the screening laboratory test within 2 weeks prior to the first administration of IP
Liver function
adequate hepatic function confirmed based on the screening laboratory test within 2 weeks prior to the first administration of IP
Subjects with adequate hematologic, hepatic, and renal functions confirmed based on the screening laboratory test within 2 weeks prior to the first administration of IP.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify